Marc Beer is the co-founder and the CEO of Renovia Inc., a biotech firm that focuses on treating pelvic floor disorders mostly urinary incontinence by developing diagnostic devices. Marc recently received a funding of $32 million and $10 million in venture debt which will be directed in researching and developing devices for the treatment of pelvic floor disorders in women.
Renovia Inc. Carries out its operations from Boston and recently launched their FDA approved device called Leva. Studies show that urinal incontinence affects close to 250 million women across the goal and Renovia Inc. Is committed to diagnosing and treating it with his advanced therapeutic devices.
A frequent investor of the biotech firm, Longwood Fund, is an investment company that focuses on health care and have been investing in Renovia since its inception. The funding as already mentioned will be used for research and development of devices that will counteract the effects of pelvic floor disorders.
Marc Beer expressed his excitement and happiness regarding the support of Longwood Fund and praised them by saying how both of them have the same vision of the future, which according to them would fill up the marketplace with their unique devices for the treatment of urinal incontinence in women.
With over two decades of experience in the development of biotech, pharmaceuticals and diagnostic devices, Marc has an extensive knowledge in these domains which has helped him devise unique strategies for speeding up the research and data collection work.
Before Renovia Inc., Marc has founded companies with a noble cause. One of them is ViaCell which specializes in preserving and extracting stem cells for research from the umbilical cord. The company grew at a very fast pace under the supervision of Marc Beer ViaCell was purchased by PerkinElmer in the year 2007.
During his tenure at ViaCell, he was simultaneously a Board Member of the pharmaceutical firm called Erytech Pharma. He managed time very well which allowed him to oversee work at more than one firm. Marc Beer held top management positions at Genzyme, and he spent most of his tenure at Genzyme as the Global Marketing head and was responsible for the product launches of three different products that were designed to tackle uncommon diseases across the world.
Prior to heading Genzyme, Marc was involved in the sales and marketing division of the diagnostic and pharmaceutical departments of Abbott Labs. His other achievements include being a former member of Mass Life Science Board and his tenure at Biotechnology Industry Organizations was also an enriching experience according to him. Apart from holding top positions in different firms, he manages to make time out of his busy schedule to actively being a part of local donations to charities and non-profit organizations that helped people around the vicinity. Learn more: https://www.benzinga.com/pressreleases/18/08/r12237847/osf-ventures-invests-in-company-developing-solutions-for-pelvic-floor-